The risk of developing chronic hepatitis B (HB) infection ranges from 90% in neonates. Perinatal or childhood infection is associated with few or no symptoms but has a high risk of becoming chronic. A limited number of medications can be used to effectively treat chronic hepatitis B. Treatment Approach: The aims of treatment of chronic hepatitis B are to achieve sustained suppression of HBV replication and remission of liver disease.
The ultimate goal is to prevent cirrhosis, hepatic failure, and hepatocellular carcinoma (HCC). Most published reports of anti-HBV therapy use changes in short-term virologic, biochemical, and histologic parameters to infer the likelihood of long-term benefit. Currently, 7 agents have been approved by the US Food and Drug Administration (FDA) for use in the treatment of adults with chronic hepatitis B in the United States Indications for hospital admission:…
